CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancerMalachi Griffith, Obi L. Griffith, Chunlei Wu et al.|Nature Genetics|2017Cited by 673
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2020Cited by 368
Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samplesErica K. Barnell, Obi L. Griffith, Peter Ronning et al.|Genetics in Medicine|2018Cited by 118
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebaseKilannin Krysiak, Zachary L. Skidmore, Arpad Danos et al.|Nucleic Acids Research|2022Cited by 46